<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047527</url>
  </required_header>
  <id_info>
    <org_study_id>DESPR DA025078</org_study_id>
    <secondary_id>R01DA025078-02</secondary_id>
    <nct_id>NCT01047527</nct_id>
  </id_info>
  <brief_title>An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence</brief_title>
  <official_title>An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The transdermal nicotine patch is the most widely used form of tobacco dependence treatment
      in the US and Europe, but most smokers are unable to successfully quit with this form of
      treatment. Failure to respond to this treatment may, to a large extent, be due to the use of
      nicotine patches for only 8 weeks, the recommended treatment duration. We have found in a
      controlled randomized clinical trial that using the nicotine patch for 24 weeks can increase
      quit rates significantly. We propose here a clinical trial to replicate and extend these
      results to a community setting in the real-world, using the same research design utilized in
      clinical trials to demonstrate the effectiveness of methadone maintenance therapy for opiate
      dependence. Specifically, 540 smokers will receive counseling and standard (8-weeks),
      extended (24-weeks), or maintenance (52 weeks) therapy with transdermal nicotine patches. The
      main outcome is biochemically-verified smoking cessation at week 52. The cost-effectiveness,
      safety, and mechanism of effect (e.g., promotion of recovery following a lapse) for
      maintenance therapy with transdermal nicotine will also be assessed. The study results may
      change how we treat nicotine dependence with transdermal nicotine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The transdermal nicotine patch is the most widely used form of tobacco dependence treatment
      in the US and Europe. Yet, abstinence rates following patch treatment are only ~20% at
      6-months and ~9% at 12-months. There is a growing recognition that nicotine dependence is a
      chronic disease, like asthma or diabetes, which requires maintenance therapy. While current
      guidelines established by the USDHHS's Public Health Service (PHS) recommend 8-week duration
      for transdermal nicotine therapy, support for this recommendation is limited. In a recent
      randomized placebo-controlled efficacy trial comparing standard (8-week) vs. extended
      (24-weeks) treatment with nicotine patches, we found that, at 24 weeks, point-prevalence
      abstinence rates were 30% in the 24-week arm vs. 20% in the standard therapy arm (p &lt; .05);
      however, by week 52, 6 months after treatment was discontinued for the extended treatment
      arm, the quit rates were equivalent across the treatment arms. This was the first clinical
      trial to suggest that the benefits of extended treatment with transdermal nicotine are
      largely dependent on the continuation of active treatment. However, as an efficacy trial,
      this study was conducted under highly-controlled conditions with strict inclusion/exclusion
      criteria to enhance internal validity. If recommendations for the duration of nicotine patch
      therapy are to be formally revised to encourage maintenance therapy, these findings must be
      replicated and extended under &quot;real-world circumstances&quot; in an effectiveness trial. In
      addition, as done in clinical trials to support the use of methadone maintenance for opiate
      dependence, a replication study must include a treatment arm that receives maintenance
      therapy throughout the duration of the trial (52 weeks). Thus, we propose to conduct a
      randomized effectiveness trial to evaluate the benefits of maintenance therapy with
      transdermal nicotine patches for smoking cessation. Specifically, 540 smokers will receive
      brief counseling and will be randomized to: standard (8-weeks), extended (24-weeks), or
      maintenance (52 weeks) transdermal nicotine therapy. The primary outcome will be
      biochemically verified 7-day point prevalence abstinence at week 52. Additional study aims
      include assessing: 1) treatment side effects across study arms; 2) longitudinal patterns of
      relapse and recovery across treatment arms; 3) mediators and moderators of treatment effects;
      and 4) cost-effectiveness. Overall, the trial findings will provide critical data for future
      PHS reviews of maintenance therapy with transdermal nicotine for subsequent treatment
      guidelines; for third-party payer assessments of maintenance transdermal nicotine as a
      covered benefit; and for individual smokers' decisions to use maintenance transdermal
      nicotine through over-the-counter access. In turn, this study may help to attain the Healthy
      People 2010 goals of reducing the US rate of tobacco use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Point Prevalence Abstinence</measure>
    <time_frame>52-week</time_frame>
    <description>self-reported abstinence from smoking for 7 days prior to the assessment and biochemically confirmed with breath carbon monoxide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Week 24 Point Prevalence Abstinence</measure>
    <time_frame>24-week</time_frame>
    <description>self-reported abstinence from smoking for 7 days prior to the assessment and biochemically confirmed with breath carbon monoxide</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">525</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>8 weeks transdermal nicotine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 weeks of transdermal nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 weeks transdermal nicotine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 weeks of transdermal nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>52 weeks transdermal nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>52 weeks of transdermal nicotine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal nicotine patch</intervention_name>
    <description>Transdermal nicotine, 21mg/day</description>
    <arm_group_label>8 weeks transdermal nicotine</arm_group_label>
    <arm_group_label>24 weeks transdermal nicotine</arm_group_label>
    <arm_group_label>52 weeks transdermal nicotine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Participants will be: 1) males and females over age 18 who smoke at
        least 10 cigarettes/day; 2) able to communicate in English; 3) able to use NRT safely
        (e.g., no allergy to latex, no serious abnormal ECG reading); 4) able to provide written
        informed consent for study procedures; and 5) residing in the geographic area for at least
        12 months.

        Exclusion Criteria: Participants will be ineligible for the trial if they: 1) are unable to
        communicate in English; 2) Have a current diagnosis of psychosis and/or manic depression;
        3) have a current medical condition that would make using transdermal nicotine patch unsafe
        (e.g., allergy to latex, serious, abnormal ECG reading)- participants with asthma,
        diabetes, hypertension, or heart disease (e.g., coronary artery disease, abnormal heart
        rhythm, an arrhythmia) will be permitted to enroll in the study with medical clearance from
        the participant's physician or the study physician; 4) have had a heart attack within the
        past 6 months, 5) are pregnant or planning to become pregnant or lactating, or 6) are
        currently enrolled or plan to enroll in another research or smoking cessation program
        within the next 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Hitsman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <results_first_submitted>May 27, 2015</results_first_submitted>
  <results_first_submitted_qc>June 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2015</results_first_posted>
  <last_update_submitted>June 10, 2015</last_update_submitted>
  <last_update_submitted_qc>June 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Robert Schnoll</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>nicotine replacement therapy, smoking cessation, transdermal nicotine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>8 Weeks Transdermal Nicotine</title>
          <description>8 weeks of transdermal nicotine
Transdermal nicotine patch: Transdermal nicotine, 21mg/day</description>
        </group>
        <group group_id="P2">
          <title>24 Weeks Transdermal Nicotine</title>
          <description>24 weeks of transdermal nicotine
Transdermal nicotine patch: Transdermal nicotine, 21mg/day</description>
        </group>
        <group group_id="P3">
          <title>52 Weeks Transdermal Nicotine</title>
          <description>52 weeks of transdermal nicotine
Transdermal nicotine patch: Transdermal nicotine, 21mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="173"/>
                <participants group_id="P3" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>8 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>24 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>8 Weeks Transdermal Nicotine</title>
          <description>8 weeks of transdermal nicotine
Transdermal nicotine patch: Transdermal nicotine, 21mg/day</description>
        </group>
        <group group_id="B2">
          <title>24 Weeks Transdermal Nicotine</title>
          <description>24 weeks of transdermal nicotine
Transdermal nicotine patch: Transdermal nicotine, 21mg/day</description>
        </group>
        <group group_id="B3">
          <title>52 Weeks Transdermal Nicotine</title>
          <description>52 weeks of transdermal nicotine
Transdermal nicotine patch: Transdermal nicotine, 21mg/day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="180"/>
            <count group_id="B2" value="173"/>
            <count group_id="B3" value="172"/>
            <count group_id="B4" value="525"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="12.3"/>
                    <measurement group_id="B2" value="46.9" spread="12.2"/>
                    <measurement group_id="B3" value="46.4" spread="12.1"/>
                    <measurement group_id="B4" value="46.4" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Point Prevalence Abstinence</title>
        <description>self-reported abstinence from smoking for 7 days prior to the assessment and biochemically confirmed with breath carbon monoxide</description>
        <time_frame>52-week</time_frame>
        <population>The primary objective of this study was to examine the benefits in terms of cessation of 52-weeks of treatment compared to 8 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard + Extended</title>
            <description>participants on standard or extended therapy</description>
          </group>
          <group group_id="O2">
            <title>Maintenance</title>
            <description>Participants on 52 weeks of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Abstinence</title>
          <description>self-reported abstinence from smoking for 7 days prior to the assessment and biochemically confirmed with breath carbon monoxide</description>
          <population>The primary objective of this study was to examine the benefits in terms of cessation of 52-weeks of treatment compared to 8 or 24 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Week 24 Point Prevalence Abstinence</title>
        <description>self-reported abstinence from smoking for 7 days prior to the assessment and biochemically confirmed with breath carbon monoxide</description>
        <time_frame>24-week</time_frame>
        <population>This analysis was planned to replicate the previous study (Schnoll et al., 2010; Annals of Internal Medicine).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard</title>
          </group>
          <group group_id="O2">
            <title>Extended + Maintenance</title>
          </group>
        </group_list>
        <measure>
          <title>Week 24 Point Prevalence Abstinence</title>
          <description>self-reported abstinence from smoking for 7 days prior to the assessment and biochemically confirmed with breath carbon monoxide</description>
          <population>This analysis was planned to replicate the previous study (Schnoll et al., 2010; Annals of Internal Medicine).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>8 Weeks Transdermal Nicotine</title>
          <description>8 weeks of transdermal nicotine
Transdermal nicotine patch: Transdermal nicotine, 21mg/day</description>
        </group>
        <group group_id="E2">
          <title>24 Weeks Transdermal Nicotine</title>
          <description>24 weeks of transdermal nicotine
Transdermal nicotine patch: Transdermal nicotine, 21mg/day</description>
        </group>
        <group group_id="E3">
          <title>52 Weeks Transdermal Nicotine</title>
          <description>52 weeks of transdermal nicotine
Transdermal nicotine patch: Transdermal nicotine, 21mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>High Blood pressure/cholesterol/blood clots</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>COPD/Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Leg infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ductal Carcinoma In Situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Lung Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Kidney Stones</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>Calculus of Galbladder; chlecystits; pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cysts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lack of placebo; low adherence to nicotine patches; nicotine patches are not the most effective treatment for nicotine dependence; participant attrition was high.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Robert Schnoll</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-7143</phone>
      <email>schnoll@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

